{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:22:46Z","timestamp":1787761366601,"version":"build-2784847793"},"posted":{"date-parts":[[2026,8,24]]},"group-title":"Endocrinology (including Diabetes Mellitus and Metabolic Disease)","reference-count":61,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"German Federal Ministry of Research, Technology and Space","award":["03LWH0181B"],"award-info":[{"award-number":["03LWH0181B"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>\n                  <jats:bold>Abstract<\/jats:bold>\n                <\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium\u2013glucose cotransporter-2 (SGLT2) inhibitors are increasingly used for type 2 diabetes. Despite established metabolic, cardiovascular, and renal benefits, it remains uncertain whether GLP-1 receptor agonists are associated with longer clinically recorded Alzheimer\u2019s disease (AD)-type dementia-free survival than sulfonylureas (SU) or SGLT2 inhibitors.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    Using\n                    <jats:italic>All of Us<\/jats:italic>\n                    electronic health records, we emulated target trials among adults aged\n                    <jats:italic>\u2265<\/jats:italic>\n                    55 years with type 2 diabetes, a 12-month washout, and no prior dementia. We compared GLP1 receptor agonists with SU and SGLT2 inhibitors. Propensity score weighting and doubly robust estimation addressed confounding. Causal survival forests estimated individualized treatment effects on 48-month RMST free from clinically recorded AD-type dementia.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>\n                    In the GLP-1 receptor agonist versus SU comparison (6,328 individuals; 48-month NNT\n                    <jats:italic>\u2248<\/jats:italic>\n                    202), initiation was associated with a small but statistically significant increase in AD-type dementia-free survival (ATE 0\n                    <jats:italic>\u00b7<\/jats:italic>\n                    21 months; 95% CI: 0\n                    <jats:italic>\u00b7<\/jats:italic>\n                    07\u20130\n                    <jats:italic>\u00b7<\/jats:italic>\n                    35). The highest-benefit stratum gained 0\n                    <jats:italic>\u00b7<\/jats:italic>\n                    45 months (95% CI: 0\n                    <jats:italic>\u00b7<\/jats:italic>\n                    28\u20130\n                    <jats:italic>\u00b7<\/jats:italic>\n                    62).\n                  <\/jats:p>\n                  <jats:p>\n                    In the SGLT2 inhibitor comparison (3,070 individuals; 48-month NNT\n                    <jats:italic>\u2248<\/jats:italic>\n                    245), the average effect was not statistically significant (ATE 0\n                    <jats:italic>\u00b7<\/jats:italic>\n                    06 months; 95% CI:\n                    <jats:italic>\u2212<\/jats:italic>\n                    0\n                    <jats:italic>\u00b7<\/jats:italic>\n                    18\u20130\n                    <jats:italic>\u00b7<\/jats:italic>\n                    31), but treatment effects were heterogeneous. The highest-benefit stratum gained 0\n                    <jats:italic>\u00b7<\/jats:italic>\n                    83 months (95% CI: 0\n                    <jats:italic>\u00b7<\/jats:italic>\n                    49\u2013 1\n                    <jats:italic>\u00b7<\/jats:italic>\n                    17). Predicted benefit was associated with older age, insulin use, lower HbA1c, and lower BMI.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>GLP-1 receptor agonists may delay clinically recorded AD-type dementia compared with SU. Comparative effectiveness versus SGLT2 inhibitors may vary, supporting study. Given hypothesis-generating findings, diabetes treatment selection should remain guided by glycemic, cardiovascular, renal, and patient-centered considerations.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Funding<\/jats:title>\n                  <jats:p>German Federal Ministry of Research, Technology and Space (03LWH0181B).<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.08.21.26361012","type":"posted-content","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:16:01Z","timestamp":1787591761000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer\u2019s disease\u2013type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning"],"prefix":"10.64898","author":[{"given":"Jonas","family":"Schr\u00f6der","sequence":"first","affiliation":[{"name":"Institute of Artificial Intelligence (AI) in Management, LMU Munich School of Management, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Geschwister-Scholl-Platz 1, 80539 Munich, Germany"},{"name":"Munich Center for Machine Learning, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Institute for Informatics, Oettingenstra\u00dfe 67, 80538 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavia-Andreea","family":"Ciora","sequence":"additional","affiliation":[{"name":"Institute of Artificial Intelligence (AI) in Management, LMU Munich School of Management, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Geschwister-Scholl-Platz 1, 80539 Munich, Germany"},{"name":"Munich Center for Machine Learning, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Institute for Informatics, Oettingenstra\u00dfe 67, 80538 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Heesen","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bendszus","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Marchioninistra\u00dfe 15, 81377 Munich, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), Munich site, Feodor-Lynen-Stra\u00dfe 17, 81377 Munich, Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Stra\u00dfe 17, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1981-7435","authenticated-orcid":false,"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, LMU University Hospital, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Nu\u00dfbaumstra\u00dfe 7, 80336 Munich, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), Munich site, Feodor-Lynen-Stra\u00dfe 17, 81377 Munich, Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Stra\u00dfe 17, 81377 Munich, Germany"},{"name":"Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, Lab Block, Charing Cross Campus, St Dunstan\u2019s Road, London W6 8RP, UK"},{"name":"School of Medicine and Population Health, University of Sheffield, Sheffield Institute for Translational Neuroscience, 385a Glossop Road, Sheffield S10 2HQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Bally","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Julie-von-Jenner-Haus, Freiburgstrasse 15, CH-3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Feuerriegel","sequence":"additional","affiliation":[{"name":"Institute of Artificial Intelligence (AI) in Management, LMU Munich School of Management, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Geschwister-Scholl-Platz 1, 80539 Munich, Germany"},{"name":"Munich Center for Machine Learning, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Institute for Informatics, Oettingenstra\u00dfe 67, 80538 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026082608400953000_2026.08.21.26361012v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30367-6"},{"key":"2026082608400953000_2026.08.21.26361012v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00249-8"},{"key":"2026082608400953000_2026.08.21.26361012v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"2026082608400953000_2026.08.21.26361012v1.4","first-page":"1","article-title":"Alzheimer Precision Medicine Initiative (APMI). The Alzheimer Precision Medicine Initiative","volume":"68","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"2026082608400953000_2026.08.21.26361012v1.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410"},{"key":"2026082608400953000_2026.08.21.26361012v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-335593"},{"key":"2026082608400953000_2026.08.21.26361012v1.7","first-page":"56","article-title":"Repurposing Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Neurodegenerative Disorders","volume":"6","year":"2026","journal-title":"Nat Aging"},{"key":"2026082608400953000_2026.08.21.26361012v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04124-5"},{"key":"2026082608400953000_2026.08.21.26361012v1.9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like Peptide-1 Receptor: Mechanisms and Advances in Therapy","volume":"9","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026082608400953000_2026.08.21.26361012v1.10","doi-asserted-by":"crossref","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The Expanding Role of GLP-1 Receptor Agonists: A Narrative Review of Current Evidence and Future Directions","volume":"86","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026082608400953000_2026.08.21.26361012v1.11","doi-asserted-by":"crossref","first-page":"e2521016","DOI":"10.1001\/jamanetworkopen.2025.21016","article-title":"Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity","volume":"8","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026082608400953000_2026.08.21.26361012v1.12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel Dual GLP-1\/GIP Receptor Agonists Show Neuroprotective Effects in Alzheimer\u2019s and Parkinson\u2019s Disease Models","volume":"136","year":"2018","journal-title":"Neuropharmacology"},{"key":"2026082608400953000_2026.08.21.26361012v1.13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","article-title":"Liraglutide in Mild to Moderate Alzheimer\u2019s Disease: A Phase 2b Clinical Trial","volume":"32","year":"2026","journal-title":"Nat Med"},{"key":"2026082608400953000_2026.08.21.26361012v1.14","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(26)00459-9","article-title":"Efficacy and Safety of Oral Semaglutide 14 Mg (Flexible Dose) in Early-Stage Symptomatic Alzheimer\u2019s Disease (Evoke and Evoke+): Two Phase 3, Randomised, Placebo-Controlled Trials","volume":"407","year":"2026","journal-title":"Lancet"},{"key":"2026082608400953000_2026.08.21.26361012v1.15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamaneurol.2025.0360","article-title":"Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis","volume":"82","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026082608400953000_2026.08.21.26361012v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02902-1"},{"key":"2026082608400953000_2026.08.21.26361012v1.17","doi-asserted-by":"crossref","unstructured":"Desai RJ , Glynn RJ , Solomon SD , Claggett B , Wang SV , Vaduganathan M . Individualized Treatment Effect Prediction with Machine Learning\u2014Salient Considerations. NEJM Evid 2024; 3: EVIDoa2300041.","DOI":"10.1056\/EVIDoa2300041"},{"key":"2026082608400953000_2026.08.21.26361012v1.18","first-page":"100570","article-title":"The All of Us Research Program: Data Quality","volume":"3","year":"2022","journal-title":"Utility, and Diversity. Patterns (N Y"},{"key":"2026082608400953000_2026.08.21.26361012v1.19","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2026082608400953000_2026.08.21.26361012v1.20","doi-asserted-by":"crossref","first-page":"102689","DOI":"10.1016\/j.eclinm.2024.102689","article-title":"Comparative Effectiveness of Glucagon-like Peptide-1 Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas on the Risk of Dementia in Older Individuals with Type 2 Diabetes in Sweden: An Emulated Trial Study","volume":"73","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026082608400953000_2026.08.21.26361012v1.21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jrsssb\/qkac001","article-title":"Estimating Heterogeneous Treatment Effects with Right-Censored Data via Causal Survival Forests","volume":"85","year":"2023","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2026082608400953000_2026.08.21.26361012v1.22","doi-asserted-by":"publisher","DOI":"10.1214\/18-AOS1709"},{"key":"2026082608400953000_2026.08.21.26361012v1.23","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1111\/ectj.12097","article-title":"Double\/Debiased Machine Learning for Treatment and Structural Parameters","volume":"21","year":"2018","journal-title":"Econom J"},{"key":"2026082608400953000_2026.08.21.26361012v1.24","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jama.2024.3376","article-title":"Using Effect Scores to Characterize Heterogeneity of Treatment Effects","volume":"331","year":"2024","journal-title":"JAMA"},{"key":"2026082608400953000_2026.08.21.26361012v1.25","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1164\/rccm.202209-1799OC","article-title":"Individualized Treatment Effects of Bougie versus Stylet for Tracheal Intubation in Critical Illness","volume":"207","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082608400953000_2026.08.21.26361012v1.26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1804597116"},{"key":"2026082608400953000_2026.08.21.26361012v1.27","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181d61eeb"},{"key":"2026082608400953000_2026.08.21.26361012v1.28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis370"},{"key":"2026082608400953000_2026.08.21.26361012v1.29","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12268"},{"key":"2026082608400953000_2026.08.21.26361012v1.30","doi-asserted-by":"crossref","first-page":"101623","DOI":"10.1016\/j.diabet.2025.101623","article-title":"Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Preventing Alzheimer\u2019s Disease, Vascular Dementia, and Other Dementia Types among Patients with Type 2 Diabetes","volume":"51","year":"2025","journal-title":"Diabetes Metab"},{"key":"2026082608400953000_2026.08.21.26361012v1.31","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2026082608400953000_2026.08.21.26361012v1.32","doi-asserted-by":"crossref","first-page":"100570","DOI":"10.1016\/j.patter.2022.100570","article-title":"The All of Us Research Program: Data Quality, Utility, and Diversity","volume":"3","year":"2022","journal-title":". Patterns (N Y"},{"key":"2026082608400953000_2026.08.21.26361012v1.33","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9718"},{"key":"2026082608400953000_2026.08.21.26361012v1.34","doi-asserted-by":"crossref","first-page":"102689","DOI":"10.1016\/j.eclinm.2024.102689","article-title":"Comparative Effectiveness of Glucagon-like Peptide-1 Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas on the Risk of Dementia in Older Individuals with Type 2 Diabetes in Sweden: An Emulated Trial Study","volume":"73","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026082608400953000_2026.08.21.26361012v1.35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41512-021-00092-9","article-title":"A Scoping Review of Causal Methods Enabling Predictions under Hypothetical Interventions","volume":"5","year":"2021","journal-title":"Diagn Progn Res"},{"key":"2026082608400953000_2026.08.21.26361012v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02902-1"},{"key":"2026082608400953000_2026.08.21.26361012v1.37","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1017\/cts.2023.635","article-title":"A Causal Roadmap for Generating High-Quality RealWorld Evidence","volume":"7","year":"2023","journal-title":"J Clin Transl Sci"},{"key":"2026082608400953000_2026.08.21.26361012v1.38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jrsssb\/qkac001","article-title":"Estimating Heterogeneous Treatment Effects with Right-Censored Data via Causal Survival Forests","volume":"85","year":"2023","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2026082608400953000_2026.08.21.26361012v1.39","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010933404324"},{"key":"2026082608400953000_2026.08.21.26361012v1.40","doi-asserted-by":"publisher","DOI":"10.1214\/18-AOS1709"},{"key":"2026082608400953000_2026.08.21.26361012v1.41","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"2026082608400953000_2026.08.21.26361012v1.42","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1111\/ectj.12097","article-title":"Double\/Debiased Machine Learning for Treatment and Structural Parameters","volume":"21","year":"2018","journal-title":"Econom J"},{"key":"2026082608400953000_2026.08.21.26361012v1.43","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jama.2024.3376","article-title":"Using Effect Scores to Characterize Heterogeneity of Treatment Effects","volume":"331","year":"2024","journal-title":"JAMA"},{"key":"2026082608400953000_2026.08.21.26361012v1.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2005.00377.x"},{"key":"2026082608400953000_2026.08.21.26361012v1.45","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1164\/rccm.202209-1799OC","article-title":"Individualized Treatment Effects of Bougie versus Stylet for Tracheal Intubation in Critical Illness","volume":"207","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082608400953000_2026.08.21.26361012v1.46","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181d61eeb"},{"key":"2026082608400953000_2026.08.21.26361012v1.47","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis370"},{"key":"2026082608400953000_2026.08.21.26361012v1.48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1804597116"},{"key":"2026082608400953000_2026.08.21.26361012v1.49","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt303"},{"key":"2026082608400953000_2026.08.21.26361012v1.50","unstructured":"Lundberg SM , Lee SI . A Unified Approach to Interpreting Model Predictions. In: Proceedings of the 31st International Conference on Neural Information Processing Systems. NIPS\u201917. Red Hook, NY, USA: Curran Associates Inc.; 2017. p. 4768\u201377."},{"key":"2026082608400953000_2026.08.21.26361012v1.51","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","article-title":"Liraglutide in Mild to Moderate Alzheimer\u2019s Disease: A Phase 2b Clinical Trial","volume":"32","year":"2026","journal-title":"Nat Med"},{"key":"2026082608400953000_2026.08.21.26361012v1.52","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(26)00459-9","article-title":"Efficacy and Safety of Oral Semaglutide 14 Mg (Flexible Dose) in Early-Stage Symptomatic Alzheimer\u2019s Disease (Evoke and Evoke+): Two Phase 3, Randomised, Placebo-Controlled Trials","volume":"407","year":"2026","journal-title":"Lancet"},{"key":"2026082608400953000_2026.08.21.26361012v1.53","doi-asserted-by":"crossref","first-page":"e70058","DOI":"10.1002\/dmrr.70058","article-title":"Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes Mellitus: A Population-Based Longitudinal Cohort Study","volume":"41","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"key":"2026082608400953000_2026.08.21.26361012v1.54","doi-asserted-by":"publisher","DOI":"10.2337\/DCI22-0034"},{"key":"2026082608400953000_2026.08.21.26361012v1.55","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes State-of-the-Art","volume":"46","year":"2021","journal-title":"Mol Metab"},{"key":"2026082608400953000_2026.08.21.26361012v1.56","doi-asserted-by":"publisher","DOI":"10.2174\/15680266113139990135"},{"key":"2026082608400953000_2026.08.21.26361012v1.57","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like Peptide-1 Receptor: Mechanisms and Advances in Therapy","volume":"9","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026082608400953000_2026.08.21.26361012v1.58","doi-asserted-by":"crossref","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The Expanding Role of GLP-1 Receptor Agonists: A Narrative Review of Current Evidence and Future Directions","volume":"86","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026082608400953000_2026.08.21.26361012v1.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04124-5"},{"key":"2026082608400953000_2026.08.21.26361012v1.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"2026082608400953000_2026.08.21.26361012v1.61","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.08.21.26361012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:40:22Z","timestamp":1787758822000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.08.21.26361012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":61,"URL":"https:\/\/doi.org\/10.64898\/2026.08.21.26361012","relation":{},"subject":[],"published":{"date-parts":[[2026,8,24]]},"subtype":"preprint"}}